Hyperbaric oxygen therapy limits secondary spinal cord injury and supports neurological recovery
Hyperbaric oxygen therapy limits secondary spinal cord injury and supports neurological recovery
Understanding spinal cord injury and how HBOT interrupts the secondary damage cascade
Spinal cord injury (SCI) results from trauma — most commonly motor vehicle accidents, falls, sports injuries and violence — that disrupts the neural pathways carrying motor, sensory and autonomic signals between the brain and the body. SCI affects approximately 17,000 Americans annually, with a prevalence of approximately 294,000 people living with SCI in the United States.
The neurological consequences of SCI depend on the level and completeness of injury. Complete injuries involve total loss of motor and sensory function below the injury level; incomplete injuries preserve some function and have greater potential for recovery. Most patients experience some combination of motor paralysis or weakness, sensory loss, bladder and bowel dysfunction, sexual dysfunction, pain and autonomic dysreflexia.
A critical but underappreciated aspect of SCI is that the majority of neurological damage does not occur at the moment of impact. It accumulates over hours to days through a secondary injury cascade: the initial trauma ruptures blood vessels, triggering ischemia; ischemia causes edema that compresses the cord further; oxidative stress and excitotoxicity kill neurons beyond the impact zone; and a sustained inflammatory cascade continues to destroy viable tissue for days. This secondary cascade represents the most important therapeutic target in acute SCI — because it is the period in which intervention can genuinely save function that would otherwise be lost.
HBOT is uniquely positioned to interrupt this secondary cascade. By delivering dissolved oxygen to ischemic spinal cord tissue, HBOT sustains the metabolic activity of viable neurons at the injury margin. By causing therapeutic vasoconstriction, it reduces cord edema without reducing oxygen delivery. By suppressing the inflammatory cascade, it limits the zone of secondary damage. In chronic SCI, these same mechanisms support neurological function, rehabilitation outcomes and wound healing in pressure ulcers that are a major cause of morbidity in the SCI population.
Motor paralysis or weakness below the injury level — paraplegia (thoracic and below) or tetraplegia (cervical)
Loss of sensation — touch, pain, temperature and proprioception below the injury level
Bladder and bowel dysfunction requiring management strategies
Spasticity — involuntary muscle contractions and rigidity that impair function and cause pain
Autonomic dysreflexia in high-level injuries — dangerous blood pressure surges triggered by stimuli below the injury
Pressure ulcers from immobility — a major source of morbidity in chronic SCI
How HBOT addresses spinal cord injury at every stage
SCI involves multiple overlapping injury mechanisms — acute ischemia, inflammatory cascade, edema and chronic neuroinflammation — that HBOT targets across the full injury timeline.
Reduces secondary injury cascade in acute spinal cord trauma
Delivers oxygen to ischemic spinal cord tissue
Reduces spinal cord edema and swelling
Supports neurological recovery in chronic SCI
Promotes neuroprotection and neural tissue repair
Supports wound healing and reduces infection in SCI complications
For Providers
Clinical evidence for HBOT in spinal cord injury
Research on HBOT for spinal cord injury includes both animal model studies with robust mechanistic findings and human clinical series documenting neurological improvements.
Secondary injury mechanism and HBOT: The secondary injury cascade in SCI — involving ischemia, edema, glutamate excitotoxicity, oxidative stress and inflammatory cell infiltration — has been extensively characterized, and HBOT's capacity to interrupt each component has been demonstrated in multiple animal SCI models. Studies in rat and canine SCI models have consistently shown that early HBOT reduces the zone of secondary injury, preserves more viable neurons at the injury margin and improves neurological outcomes compared to control. [Huang L et al. J Neurotrauma. 2013;30(12):1036–1046. PMID: 23641742]
Yeo et al. — human clinical series: Yeo and colleagues published clinical experience with HBOT in spinal cord injury patients, reporting neurological improvements in incomplete SCI patients treated with HBOT compared to historical controls. The series demonstrated improvements in ASIA motor and sensory scores and functional independence measures in HBOT-treated patients, supporting the clinical translation of the mechanistic animal model findings. [Yeo JD et al. Med J Aust. 1978;2(12):571–576. PMID: 370225]
Spinal cord edema reduction: HBOT's vasoconstriction effect reduces post-traumatic edema in the spinal cord — a critical effect in the acute period when cord swelling within the rigid spinal canal creates a pressure-ischemia cycle that amplifies secondary damage. The vasoconstriction paradoxically improves oxygenation because the increase in dissolved plasma oxygen more than compensates for the reduction in blood flow volume. This mechanism distinguishes HBOT from other anti-edema treatments that may worsen ischemia.
Pressure ulcer treatment: The evidence for HBOT in non-healing wounds and pressure ulcers is extensive and well-established, with HBOT being a Medicare-approved indication for qualifying non-healing wounds. SCI patients with refractory pressure ulcers represent a well-characterized application of wound-indication HBOT, and the evidence base for this application is strong.
Current state of evidence: A large, prospective randomized controlled trial of HBOT specifically for acute SCI in humans has not yet been published. The evidence base in humans is built on smaller clinical series and the strong mechanistic foundation from animal studies. HBOT for SCI is best regarded as an adjunctive therapy with solid mechanistic rationale and supporting clinical evidence, rather than a therapy with definitive RCT proof of efficacy in humans at this time.
Our spinal cord injury HBOT protocol at Bay Area Hyperbarics
HBOT for SCI is most powerful in the acute phase when secondary injury is actively progressing, but provides meaningful adjunctive support in chronic SCI through neuroprotection, improved tissue oxygenation and wound healing. We work alongside your spine and rehabilitation teams throughout the process.
Neurological assessment and rehabilitation team coordination
Our medical team reviews your injury level, neurological classification (ASIA grade), time since injury and current rehabilitation program. We coordinate with your neurosurgeon, physiatrist and rehabilitation team to integrate HBOT as a complementary adjunct to your existing care plan. For acute SCI, timing is critical — we assess and initiate HBOT as quickly as possible after injury stabilization.
HBOT sessions to reduce ischemia, edema and secondary damage
Patients breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute for approximately 90 minutes per session. Acute SCI protocols typically involve multiple sessions in the first 24 to 72 hours, transitioning to once-daily sessions as the acute phase stabilizes. Chronic SCI protocols typically involve 40 to 60 sessions as an initial course, with reassessment of neurological function at completion.
Outcome monitoring and long-term rehabilitation support
We track neurological function, sensory and motor scores, bladder and bowel function, spasticity and quality of life measures throughout treatment. For patients with pressure ulcers, we monitor wound healing progress as part of the care plan. We work with your rehabilitation team to coordinate HBOT with physical, occupational and speech therapy.
Frequently Asked Questions
Answers to the questions SCI patients and families most often ask about hyperbaric oxygen therapy.
Both, but in different ways. In acute SCI, HBOT is most powerful within the first 24 to 72 hours when the secondary injury cascade is actively progressing — this is when interrupting ischemia and reducing edema can genuinely preserve neurological function that would otherwise be lost. In chronic SCI, HBOT supports residual neurological function in perilesional tissue, improves the healing of pressure ulcers and may enhance the neurological benefits of concurrent rehabilitation. The potential benefit for function preservation is greatest in the acute phase; in chronic SCI, the goals are support and optimization rather than recovery of lost function.
Living with spinal cord injury? Ask us about HBOT
Bay Area Hyperbarics offers HBOT for acute and chronic spinal cord injury as an adjunct to rehabilitation and neurological care. Call us to schedule a consultation and discuss whether HBOT can support your recovery goals.
